Earnings Call · Q1 FY2023·2023-05-12

Q1 23EPS +2.25%·Rev n/aQ4 22EPS -6.02%·Rev n/aQ3 22EPS +14.29%·Rev n/aQ2 22EPS +18.18%·Rev n/a⚠ consensus missing

RELMADA THERAPEUTICS, INC. RLMD

Tim McCarthy — Investor Relations or Communications

Sergio Traversa — Chief Executive Officer

Cedric O'Gorman — Chief Medical Officer

Maged Shenouda — Chief Financial Officer

−3.1%1d on move date−2.9% vs SPY3d−5.5%5d−5.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RLMD calls or request research access.

More RLMD calls Browse calls Request research access